Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp movement.
This is particularly true of small-cap biotech stocks. In many cases, these are unprofitable companies with little to no revenue. However, these are also the companies that can provide the highest return for risk-tolerant investors.
